Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Berkelium is a synthetic, radioactive chemical element with the symbol Bk and atomic number 97, belonging to the actinide series (Royal Society of Chemistry, 2024). It was first synthesized in 1949 at the University of California, Berkeley, by bombarding americium-241 with alpha particles (Los Alamos National Laboratory, 2024). Berkelium has no known biological function and is not considered a therapeutic target in any medical context (Wikipedia, 2024). Instead, it is primarily used in basic scientific research, specifically as a target material for the synthesis of even heavier transuranic elements like tennessine (PubChem, 2024). Because of its intense radioactivity, berkelium is highly toxic and can accumulate in the skeletal system if ingested or inhaled, posing a severe health hazard (Lenntech, 2024). There are currently no drugs that interact with berkelium as a target, nor are there any clinical applications for this element in human medicine.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Berkelium (Bk).